Immuvera Therapeutics receives EMA Limited Market Authorisation and advances to registration study
Immuvera Therapeutics today announces that the European Medicines Agency (EMA) has granted a Limited Market Authorisation (LMA) for our lead veterinary medicine—an important milestone for animals with high unmet medical need.
Written by
Immuvera
What this means
The LMA pathway enables earlier availability in veterinary limited markets while maintaining rigorous safety and quality standards, including ongoing pharmacovigilance and evidence generation.
Next step: randomized registration study
We will conduct and finalize a randomized clinical study in dogs as quickly as possible to support a subsequent full market approval.
Design & endpoints: The study is structured as a registration (pivotal) trial with median overall survival (mOS) and quality of life (QoL) as key endpoints.
Geographies: Multicentre execution across Spain, Portugal, Italy, and Germany.
Commitment: Speed with scientific rigor, close collaboration with investigators and regulators, and continuous post-authorisation monitoring.
“Securing LMA is a major step for Immuvera—and our commitment now is to deliver the randomized registration study with urgency and rigor so we can progress toward full approval.”
— Jørund Sollid, CEO, Immuvera Therapeutics
